MedPath

Clinical Evaluation of Daptomycin Bone Penetration

Conditions
Bone and Joint Infections
Registration Number
NCT01306825
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

Bone and joint infections are commonly due to Gram-positive bacteria. Treatment of these infections is difficult because of the need of prolonged duration of antimicrobial agents in combination with surgical procedure. Moreover, in recent years, a growing resistance pattern to various antimicrobial agents has been observed for Gram-positive bacteria. Consequently, there is an urgent need for new drugs with high bone penetration for the treatment of those infections. The investigators hypothesized that daptomycin allow to achieve high concentrations in bone compartments.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients' percentage of which the intra-osseous daptomycin concentration is ≥ 8 times MIC (if available) or ≥ 8 times critical concentration (if Bacteriological documentation is unavailable)5 min before started administration of daptomycin, 5 min after administration of daptomycin and at random after perfusion of daptomycin
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Service d'Orthopédie - Hôpital Centre de Chirurgie Orthopédie et de la Main (CCOM) - Hôpitaux Universitaires de Strasbourg - 10 av Achille Baumann -

🇫🇷

Illkirch-Graffenstaden, France

Plateau Technique de Microbiologie - Hôpitaux Universitaires de Strasbourg - 1, rue Koeberlé

🇫🇷

Strasbourg, France

Service des maladies infectieuses et tropicales - Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath